Relmada Therapeutics, Inc. (RLMD)

NCM – Real Time Price. Currency in USD

4.78

+0.31 (6.94%)

Market open: Aug 12, 2026, 11:28 AM EDT

4.47

0.00 (0.00%)

Previous after-hours: Aug 11, 2026, 7:34 PM EDT

11.08.2026

Down 29.6% in 4 Weeks, Here's Why Relmada Therapeutics (RLMD) Looks Ripe for a Turnaround

Relmada Therapeutics (RLMD) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

07.08.2026

Relmada Therapeutics Q2 Earnings Call Highlights

Relmada Therapeutics NASDAQ: RLMD said it is prioritizing manufacturing activities for NDV-01, its sustained-release intravesical formulation of gemcitabine and docetaxel for non-muscle invasive bladder cancer, as it targets an investigational new drug application filing by the end of 2026.

07.08.2026

Relmada Therapeutics, Inc. (RLMD) Q2 2026 Earnings Call Transcript

Videos

No Data

There is no data to display

Relmada Therapeutics, Inc. (RLMD)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Relmada Therapeutics, Inc. (RLMD)

Down 29.6% in 4 Weeks, Here's Why Relmada Therapeutics (RLMD) Looks Ripe for a Turnaround

Relmada Therapeutics Q2 Earnings Call Highlights

Relmada Therapeutics, Inc. (RLMD) Q2 2026 Earnings Call Transcript

Videos

No Data

Down 29.6% in 4 Weeks, Here's Why Relmada Therapeutics (RLMD) Looks Ripe for a Turnaround

Relmada Therapeutics Q2 Earnings Call Highlights

Relmada Therapeutics, Inc. (RLMD) Q2 2026 Earnings Call Transcript

Videos

No Data

Search stocks

Relmada Therapeutics, Inc. (RLMD)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Relmada Therapeutics, Inc. (RLMD)

Down 29.6% in 4 Weeks, Here's Why Relmada Therapeutics (RLMD) Looks Ripe for a Turnaround

Relmada Therapeutics Q2 Earnings Call Highlights

Relmada Therapeutics, Inc. (RLMD) Q2 2026 Earnings Call Transcript

Videos

No Data

Down 29.6% in 4 Weeks, Here's Why Relmada Therapeutics (RLMD) Looks Ripe for a Turnaround

Relmada Therapeutics Q2 Earnings Call Highlights

Relmada Therapeutics, Inc. (RLMD) Q2 2026 Earnings Call Transcript

Videos

No Data